Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping
- PMID: 10579482
- DOI: 10.1016/S0009-9236(99)70018-4
Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping
Abstract
Most dextromethorphan CYP2D6 phenotyping studies use a 30-mg dose, but data that show superiority of any particular dose are lacking. We compared metabolic ratios from six different dextromethorphan phenotyping doses to ascertain whether linearity existed over a dosage range. Forty subjects were enrolled in the study. Each subject received 0.05 mg/kg, 0.15 mg/kg, 0.3 mg/kg, 30 mg, 0.8 mg/kg, and 1.2 mg/kg dextromethorphan in a randomized crossover fashion. Urinary dextromethorphan to dextrorphan molar ratios were used to measure CYP2D6 activity. Single blood samples were obtained for CYP2D6 genotyping, which revealed one poor metabolizer and 39 extensive metabolizers. A statistical difference was found for the molar ratio between the 0.8 mg/kg and the 1.2 mg/kg dose compared with the other four doses. None of the 39 genotypic extensive metabolizers were incorrectly phenotyped with any of these doses. These data support the use of moderate doses of dextromethorphan for phenotyping to avoid dose dependency.
Similar articles
-
Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity.J Pharmacol Exp Ther. 1998 Jun;285(3):955-60. J Pharmacol Exp Ther. 1998. PMID: 9618394
-
Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.Clin Pharmacol Ther. 1996 May;59(5):583-92. doi: 10.1016/S0009-9236(96)90187-3. Clin Pharmacol Ther. 1996. PMID: 8646830
-
Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.Clin Pharmacol Ther. 2005 Dec;78(6):664-74. doi: 10.1016/j.clpt.2005.09.001. Clin Pharmacol Ther. 2005. PMID: 16338282 Clinical Trial.
-
[Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].Psychiatr Pol. 2004 Nov-Dec;38(6):1093-104. Psychiatr Pol. 2004. PMID: 15779673 Review. Polish.
-
Low frequency of dextromethorphan O-demethylation deficiency in a Chinese population.Clin Pharmacol Ther. 1996 Dec;60(6):696-8. doi: 10.1016/S0009-9236(96)90219-2. Clin Pharmacol Ther. 1996. PMID: 8988073 Review. No abstract available.
Cited by
-
Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.Eur J Clin Pharmacol. 2005 Dec;61(11):821-9. doi: 10.1007/s00228-005-0051-5. Epub 2005 Nov 17. Eur J Clin Pharmacol. 2005. PMID: 16315033
-
Prediction and visualization of CYP2D6 genotype-based phenotype using clustering algorithms.Transl Clin Pharmacol. 2017 Sep;25(3):147-152. doi: 10.12793/tcp.2017.25.3.147. Epub 2017 Sep 15. Transl Clin Pharmacol. 2017. PMID: 32095466 Free PMC article.
-
Addressing phenoconversion: the Achilles' heel of personalized medicine.Br J Clin Pharmacol. 2015 Feb;79(2):222-40. doi: 10.1111/bcp.12441. Br J Clin Pharmacol. 2015. PMID: 24913012 Free PMC article. Review.
-
Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.Eur J Clin Pharmacol. 2007 Apr;63(4):321-33. doi: 10.1007/s00228-006-0250-8. Epub 2007 Feb 2. Eur J Clin Pharmacol. 2007. PMID: 17273835 Review.
-
Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial.Clin Pharmacokinet. 2020 Jul;59(7):927-939. doi: 10.1007/s40262-020-00862-6. Clin Pharmacokinet. 2020. PMID: 32060866 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources